A 33-year-old man with COVID-19 presented with subacute thyroiditis: A rare case report and literature review

L. Davoodi1, Z. Oladi2, H. Jafarpour3, Z. Zakariaei4, E. Soleymani5 and A. Razavi3

1) Department of Infectious Diseases, School of Medicine, Antimicrobial Resistance Research Centre, Communicable Diseases Research Institutes, 2) Department of Internal Medicine, School of Medicine, Ghaem Shahr Razi Hospital, 3) Student Research Committee, School of Medicine, 4) Department of Emergency Medicine, School of Medicine, Orthopedic Research Centre, Ghaem Shahr Razi Hospital, Mazandaran University of Medical Sciences, Sari and 5) Student Research Committee, Hamadan University of Medical Science, Hamadan, Iran

Abstract

We report the first case of the novel coronavirus disease 2019 (COVID-19) presenting with subacute thyroiditis in Ghaemshar, Mazandaran Province, Iran. In our patient, with the initiation of corticosteroid therapy, the symptoms of subacute thyroiditis gradually disappeared with a slow increase in thyroid-stimulating hormone (TSH) and the gradual elimination of thyrotoxicosis. This case shows that decreased TSH and persistent thyrotoxicosis may make the patient’s condition worse. Managing this complication can take several weeks and can be complicated.

Keywords: Coronavirus disease 2019, corticosteroid therapy, infection, subacute thyroiditis, thyroid-stimulating hormone

Original Submission: 16 December 2020; Revised Submission: 27 February 2021; Accepted: 11 March 2021

Article published online: 22 March 2021

Case report

A 33-year-old man presented to the clinic with fever (38.5°C), sore throat, body aches and lethargy for 2 days on 25 September 2020. Throat examination and lung auscultation were normal. Initial laboratory tests on admission to the clinic showed an elevated white blood cell count (2335 × 10⁹/L), high C-reactive protein level (CRP) (46 mg/L; normal <10 mg/L), normal haemoglobin level (14.1 g/dL) and thrombocytopenia (142 × 10³/μL). Because of the clinical features and the COVID-19 pandemic, a nasopharyngeal swab was used for sampling, and SARS-CoV-2 nucleic acid was detected by RT-PCR test; acetaminophen, naproxen and diphenhydramine were prescribed. On the sixth day, he presented to the Emergency Room with fever (39°C) and chills, sweating, sore throat and dry cough. Except for the heart rate (over 100 beats per min (bpm)), all other vital signs were in the normal range. Electrocardiogram revealed sinus tachycardia. After admission, a lung CT scan showed bilateral peripheral ground-glass opacification (Fig. 1).
Due to ground-glass opacification and clinical symptoms, nasopharyngeal swabs were used for sampling, and SARS-CoV-2 nucleic acid was detected again by RT-PCR. By controlling the patient’s fever with injected acetaminophen, heart rate decreased to 90 bpm. In laboratory tests, troponin and electrolytes were normal. Interleukin-6 and D-dimer were 11 pg/mL (normal <6 pg/mL) and 156 μg/mL (normal <1 μg/mL), respectively. Remdesivir 200 mg on the first day, followed by 100 mg daily with enoxaparin 60 mg started for 4 days. On the 8th day, the general condition of the patient improved, but he complained of a sore throat. On re-examination, we noticed a slight tenderness in the neck in the thyroid area. On thyroid ultrasound, a heterogeneous thyroid gland with bilateral ill-defined hypoechoic areas revealed SAT. No cervical lymphadenopathy was noted.

His laboratory tests revealed elevated erythrocyte sedimentation rate (84 mm/h, normal <15 mm/h) and CRP (37.9 mg/L, normal <10 mg/L), but normal platelet and leucocyte counts. His thyroid function tests were thyroid-stimulating hormone (TSH) < 0.001 mU/L, total thyroxine 23.1 μg/dL (normal range 4–11 μg/dL) and total tri-iodothyronine 236 ng/dL (normal range 75–195 ng/dL) (Table 1). Thyroperoxidase antibody and thyrotropin receptor antibody were negative (Table 1). In blood culture, after 48 hours of incubation, bacterial culture was negative. Autoimmune thyroiditis, Graves’ disease and infectious thyroiditis were ruled out because of negative results for thyrotropin receptor antibody and thyroperoxidase antibody as well as the lack of bacterial growth in blood cultures after 48 hours of incubation. Eventually, given the recent COVID-19 infection, it was suspected that the SAT was caused by COVID-19. The patient was treated with dexamethasone 4 mg every 8 hours for 5 days. He was discharged with oral prednisone 25 mg daily with taper prescribed. Patient follow up was performed 10 days, 1 month and 45 days later with thyroid function tests (Table 1).

**Discussion**

Subacute thyroiditis is a self-limiting thyroid disorder associated with a three-stage clinical course of an initial thyrotoxic phase, hypothyroidism and return to normal thyroid function within 3 months [5]. This complication is one of the uncommon causes of thyrotoxicosis and is characterized by a painful tenderness in the thyroid gland with referred pain to the ear along with symptoms such as fever, lethargy and anorexia [6]. The exact cause of SAT is not known, but several viruses (such as influenza virus, Epstein–Barr virus, hepatitis E virus, cytomegalovirus, mumps virus, human immunodeficiency virus and chickenpox virus) have been conjectured to stimulate SAT through inducing direct or indirect damage through the circulation of the viral genome or virus-specific antibodies [7]. It seems that SARS-CoV-2 can cause SAT [8]. In the cases we examined, patients with COVID-19 developed SAT after partial recovery (Table 2)[4,9–13]. The minimum and maximum intervals from the onset of COVID-19 symptoms to the onset of SAT symptoms is 4 days [11] to 30 days [10](Table 2). Also, the minimum and maximum intervals between the onset of SAT symptoms and SAT recovery are 4 weeks [11] to 10 weeks [4,12] (Table 2). In our case, the interval between the onset of the first symptoms of COVID-19 and the onset of SAT symptoms and the interval between the onset of SAT symptoms and recovery were 10 days and 7 weeks, respectively (Table 2).

**TABLE 1. Thyroid function tests at multiple time-points during the patient’s illness**

| Laboratory tests (normal ranges) | Dates of thyroid function tests |
|----------------------------------|--------------------------------|
|                                  | 2 October 2020 | 6 October 2020 | 16 October 2020 | 6 November 2020 | 21 November 2020 |
| TSH (0.5–5.0 mUI/L)              | <0.001          | <0.01          | <0.01          | 0.1             | 2.5             |
| tT4 (4–11 μg/dL)                 | 22.1            | 18.5           | 18.9           | 14.3            | 6.6             |
| tT3 (75–195 ng/dL)               | 236             | 221            | 229            | 211             | 189             |
| Anti-TPO                         | Negative        | Negative       | Negative       | Negative        | Negative        |
| TRAb                             | Negative        | Negative       | Negative       | Negative        | Negative        |

Abbreviations: anti-TPO, thyroperoxidase antibody; TRAb, thyrotropin receptor antibody; TSH, thyroid-stimulating hormone; tT3, total tri-iodothyronine; tT4, total thyroxine.

Values in bold type indicate abnormal laboratory test results.

FIG. 1. Chest CT showed bilateral peripheral ground-glass opacification.
### TABLE 2. Patient clinical, biochemical and imaging features

| Case            | Place       | Gender | Age (years) | COVID-19 signs | Time from COVID-19 onset to SAT, day | SAT signs | TFTs upon admission | Thyroid imaging | Time from SAT onset to recovery, week | TFTs after recovery |
|-----------------|-------------|--------|-------------|----------------|-------------------------------------|-----------|---------------------|-----------------|--------------------------------------|--------------------|
| Mehmoed et al.  | —           | Female | 29          | Fever (38.3°C), dyspnoea | 10 | anterior neck tenderness, bilateral hand tremors, odynophagia, sweating, tachycardia (130 bpm), palpable left thyroid lobe | fT4: high | cT3: high | TSH: low Anti-TPO: negative TRAb: negative | —                  | 10 | —                                  |
| Chakraborty et al. | India      | Male   | 58          | Fever (37.5°C), tachycardia (104 bpm) | 4 | fever (38.5°C), neck tenderness and swelling, tachycardia (116 bpm) | fT4: high | cT3: high | TSH: low Anti-TPO: negative TRAb: negative | Ultrasonography: diffuse swelling of the thyroid gland with hypo-echogenicity and a solitary nodule in each lobe, reduced uptake in the thyroid scan using 99m Tc Colour Doppler: increased vascularity of the thyroid gland | 4 | fT4: low | cT3: low | TSH: high Anti-TPO: negative TRAb: negative | —                  |
| Mattar et al.   | Myanmar     | Male   | 34          | Fever (37.7°C), dry cough, headache and anosmia | 10 | anterior neck tenderness, diffuse asymmetric goitre, tachycardia (90–120 bpm) | fT4: high | cT3: high | TSH: low Anti-TPO: negative TRAb: negative | Ultrasonography: enlarged thyroid gland with heterogeneous echotexture with hypo-echogenicity Colour Doppler: reduced blood flow in both lobes | 10 | fT4: normal | cT3: normal | TSH: normal Anti-TPO: — | TRAb: — |
| Brancatella et al. | Italy       | Female | 18          | Fever (37.5°C), fatigue, palpitation, neck pain | 18 | Fever (37.5°C), fatigue, palpitation, neck pain | fT4: high | cT3: high | TSH: low Anti-TPO: negative TRAb: negative | Ultrasonography: bilateral hypoechogenic areas with low to absent vascularityization | 6 | fT4: — | cT3: — | TSH: normal Anti-TPO: — | TRAb: — |
| Campos-Barrera  | Mexico      | Female | 37          | Odynophagia, anemia | 30 | Radiating neck pain | fT4: high | cT3: high | TSH: undetectable Anti-TPO: negative TRAb: negative | No uptake in the iodine thyroid 8 scan | — | fT4: — | cT3: — | TSH: low Anti-TPO: — | TRAb: — |
| Khatri et al.   | USA         | Female | 41          | Fever, cough, coryza | 14 | Anterior neck pain, neck swelling, odynophagia, fever (39.5°C), tachycardia (112 bpm), irritability, headaches, bilateral hand tremors, palpitations | cT4: - | cT3: - | TSH: low Anti-TPO: - TRAb: - | Ultrasonography: heterogeneous thyroid gland with bilateral hypoechogenic areas | 9 | cT4: normal | cT3: normal | TSH: normal Anti-TPO: negative TRAb: negative | —                  |
| Our case        | Iran        | Male   | 33          | Fever (38.5°C), myalgia, fatigue | 10 | Fever (39°C), sweating, dry cough, neck tenderness, tachycardia (>100 bpm) | cT4: high | cT3: high | TSH: low Anti-TPO: negative TRAb: negative | Ultrasonography: heterogeneous thyroid gland with bilateral ill-defined hypoechogenic areas | 7 | cT4: normal | cT3: normal | TSH: normal Anti-TPO: negative TRAb: negative | —                  |

Abbreviations: anti-TPO, thyroperoxidase antibody; COVID-19, coronavirus disease 2019; fT3, free tri-iodothyronine; fT4, free thyroxine; TFT, thyroid function test; TRAb, thyrotropin receptor antibody; TSH, thyroid-stimulating hormone; tT3, total tri-iodothyronine; tT4, total thyroxine.

Diagnosis of this complication is usually clinical, with confirmation by laboratory tests and neck imaging. Increased erythrocyte sedimentation rate (>50 mm/h), elevated CRP, low TSH and high levels of thyroid hormones and thyroglobulin along with absent/low titres of serum thyroperoxidase and thyroglobulin antibodies confirm the diagnosis of SAT [9]. In imaging techniques, during the acute phase, in the radionuclide thyroid scan the amount of tracer uptake is usually reduced or absent, while thyroid ultrasound shows bilateral hypoechogenic areas with reduced or no vascularityization [13]. In our patient’s ultrasound, bilateral hypoechogenic areas were diagnosed. In our patient, because of negative thyrotropin receptor antibody and thyroperoxidase antibody as well as negative blood culture 48 hours after incubation, autoimmune thyroiditis, Graves’ disease and infectious thyroiditis were ruled out.
The incidence of SAT is 12.1 per 100 000/year and is more prevalent in young women than men (19.1 versus 4.1 per 100 000/year, respectively) [14,15]. Although COVID-19 covers a relatively wide range of clinical manifestations [16], the occurrence of SAT is very low among patients with the disease [4]. Nearly all COVID-19 patients with SAT have been female [9,10], with the exception of four middle-aged men in recent reports (Table 2) [4,8,11].

Evidence from a previous coronavirus outbreak in 2002 demonstrated that among 61 survivors of severe acute respiratory syndrome (SARS) who had no previous endocrine disease and were studied 3 months after recovery, four patients (6.6%) were diagnosed with primary hypothyroidism [17], and thyroid lesions were found in the autopsies of people who died of SARS [18]. Given that SARS-CoV-2 and SARS-CoV are in the same family, there is a possibility that COVID-19 also has the potential to impair thyroid function [19]. It has been reported that messenger RNA encoding expression for the angiotensin-converting enzyme 2 receptor in thyroid follicular cells makes them a potential target for SARS-CoV-2 entry [20]. Moreover, the inflammatory response may cause local damage and apoptosis of thyroid cells [9].

In a single-centre prospective study, low PCR cycle threshold values of SARS-CoV-2 and CRP were independently associated with low TSH (p 0.030) and low free tri-iodothyronine (p 0.007), respectively. Furthermore, the decrease in free tri-iodothyronine was associated with an increase in COVID-19 intensity (p 0.032). In other words, patients with low free tri-iodothyronine had more adverse results than other patients [21]. A separate study illustrates that a significant number of COVID-19 patients who require intensive care develop thyrotoxicosis and decreased TSH concentrations, in line with the SAT induced by SARS-CoV-2. In our patient, with the initiation of corticosteroid therapy, the symptoms of SAT gradually disappeared with a slow increase in TSH, and the gradual elimination of thyrotoxicosis. Therefore, the diagnosis and treatment of thyroid disorders, including SAT, in patients with COVID-19, especially those in need of intensive care, should not be neglected [22].

Remdesivir is a drug previously used to treat Ebola virus infection [23,24], but in randomized clinical trials, positive results were obtained from the use of this drug in COVID-19 therapy and it has been approved for use in COVID-19 by the US Food and Drug Administration [25]. However, the use of this drug is associated with some side effects. The most common adverse effects are nausea and elevated liver transaminases, which have been reported in patients with COVID-19 and Ebola virus infection [24]. To date, no adverse effects of thyroiditis have been reported with this drug. Therefore, in our patient, the occurrence of SAT due to the use of remdesivir seems unlikely. In patients with COVID-19 who develop SAT, care should be taken in their treatment so that they do not develop hypothyroidism later, as reported in an 58-year-old Indian man (Table 2) [11].

The exact mechanism of SAT development due to COVID-19 is not known, but it can be controlled and treated using corticosteroids. Although COVID-19 presenting with SAT is a rare condition, regardless of gender, we need to be watchful about the potential complications of SAT as an important and treatable status for COVID-19 especially in patients with severe conditions.

**Funding**

We did not receive any funding for this research.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Ethical approval and informed consent**

The form is approved by the Ethics Committee in Biomedical Research of Mazandaran University of Medical Sciences. Written informed consent was obtained from the patient for the publication of this case report as well as accompanying images. A copy of the written consent is available for review by the editor-in-chief of this journal.

**Acknowledgements**

Special thanks to the Student Research Committee of Mazandaran University of Medical Sciences for supporting us in this project.

**References**

[1] Razavi A, Davoodi L, Shojaei L, Jafarpour H. Covid-19 in children: a narrative review. Open Access Macedonian J Med Sci 2020;8(T1): 23–31.

[2] Liu X, Zhou L, Zhu Y. Report on a lactating patient with COVID-19. Infection 2020;48:1–5.

[3] Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A. Hydroxychloroquine-induced Stevens–Johnson syndrome in COVID-19: a rare case report. Oxford Med Case Rep 2020;2020(6).
[4] Mattar SAM, Koh SJQ, Chandran SR, Cherrng BPZ. Subacute thyroiditis associated with COVID-19. BMJ Case Rep 2020;13(8):e237336.
[5] Rothacker KM, Walsh JP. Acute and subacute thyroiditis. In: Vitti P, Hegedus L, editors. Thyroid diseases: pathogenesis, diagnosis and treatment. Heidelberg: Springer International Publishing; 2016. p. 1-21.
[6] Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, et al. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 2008;47:725-9.
[7] Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009;6(1):5.
[8] Sohrabpour S, Heidari F, Karimi E, Ansari R, Tajdini A, Heidari F. Subacute thyroiditis in COVID-19 patients. Eur Thyroid J 2020;9:322-4.
[9] Khazri A, Charlap E, Kim A. Subacute thyroiditis from COVID-19 infection: a case report and review of literature. Eur Thyroid J 2020;9:309-13. 1-5.
[10] Campos-Barrera E, Alvarez-Cisneros T, Davalos-Fuentes M. Subacute thyroiditis associated with COVID-19. Case Rep Endocrinol 2020;2020:8891539.
[11] Chakraborty U, Ghosh S, Chandra A, Ray AK. Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity. BMJ Case Rep 2020;13(12):e239953.
[12] Mehmood MA, Bapna M, Arshad M. A case of post-COVID-19 subacute thyroiditis. Cureus 2020;12:e12301.
[13] Brancatella A, Ricci D, Viola N, Sgro D, Santini F, Latrofa F. Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab 2020;105:2367–70. dga2276.
[14] Fazourechi V, Aniszewski JP, Fazourechi GZE, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 2003;88:2100-5.
[15] Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metabol 2009;94:1853–78.
[16] Davoodi L, Jafarpour H, Taghavi M, Razavi A. Covid-19 presented with deep vein thrombosis: an unusual presenting. J Invest Med High Impact Case Rep 2020;8. 2324709620931239.
[17] Leow MKS, Kwek DSK, Ng AWK, Ong KC, Kaw GJL, Lee S. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol 2005;63:197–202.
[18] Wei L, Sun S, Xu CH, Zhang J, Xu Y, Zhu H, et al. Pathology of the thyroid in severe acute respiratory syndrome. Hum Pathol 2007;38:95–102.
[19] Gorini F, Bianchi F, Iervasi G. COVID-19 and thyroid: progress and prospects. Basel: Multidisciplinary Digital Publishing Institute; 2020.
[20] Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest 2020;1–6.
[21] Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, et al. Thyroid dysfunction in relation to immune profile, disease status and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab 2020.
[22] Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabet Endocrinol 2020;8:739–41.
[23] Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293–303.
[24] Jorgensen SC, Kebrisai R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacother J Hum Pharmacol Drug Ther 2020;40:659–71.
[25] Lamb YN. Remdesivir: first approval. Drugs 2020;80:1355–63.